Author Affiliations: Alta Bates Summit Medical Center, Department of Medicine, University of California, San Francisco, Oakland (Dr Stollman); and Department of Medicine, University of Washington, Seattle (Dr Surawicz).
Kassam and colleagues1 are to be congratulated on their series of patients successfully treated with “fecal transplant” for refractory or recurrent Clostridium difficile–related disease, demonstrating greater than 90% success rates—highly consistent with prior data, including ours.2
Stollman N, Surawicz C. Fecal Transplant for Clostridium difficile. Arch Intern Med. 2012;172(10):825-826. doi:10.1001/archinternmed.2012.1055